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Abstract
Background To evaluate uveitis care outcomes in standalone versus a combined ophthalmology-rheumatology
clinic.
Methods Participants were patients aged 18 years and older with a minimum 12-month history of chronic uveitis
prior to being referred to the combined uveitis clinic at Kresge Eye Institute and who were treated in the combined
clinic for at least 6 months. Best corrected visual acuity (BCVA), objective markers of inflammation, and achieving
targeted dose of immunomodulatory therapy (IMT) were compared in the cohort of uveitis patients 6 months prior to
and after the initial evaluation in the combined clinic.
Results Sixty-six percent of study participants were female with a mean age of 51.5 years. BCVA improved from 0.58
logMAR (Snellen: ~20/74) at the initial combined clinic visit to 0.50 logMAR (Snellen: ~20/63) 6 months after the first
combined visit (p = 0.0137). The establishment of the combined uveitis clinic led to higher frequency of patients at
target dose of IMT: an increase from 49.0% at 6 months prior to the combined visit to 70.1.4% and 79.8% at the initial
combined visit and 6 months after the combined visit, respectively.
Conclusion A combined model of management for chronic uveitis patients wherein rheumatological services are
coupled with ophthalmic care leads to improvement in patient clinical outcomes and achieving target therapy.
Keywords Uveitis, Combined clinic, Rheumatology, Steroid sparing therapy, Immunomodulatory therapy
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Introduction
Uveitis is a rare ocular condition characterized by intraocular inflammation, the etiology of which can be autoimmune or secondary to infections [1]. The prevalence of
uveitis is estimated to approach 133 per 100 000 [2–5].
Repeated active inflammation can irreversibly damage
ocular structures and eventually cause significant deterioration in vision [6]. In addition, the majority of patients
who suffer from uveitis are in their working age and it
can cause significant decrease in productivity [7]. Uveitis
is reported to be the fifth or sixth leading cause of blindness in working age populations in developed countries
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[8–10]. Therefore, prompt and proper management of
uveitis is critical to minimize vision loss and medical burden in patients.
The goal of noninfectious uveitis treatment is to suppress ocular inflammation to prevent further damage
to the ocular visual system [7]. Corticosteroids are the
mainstay of treatment for uveitis since their initial use
in the 1950s [11]. However, due to the local and systemic
side effects of prolonged corticosteroid usage, treatment
of noninfectious uveitis frequently requires systemic
steroid sparing immunomodulatory therapy (IMT). The
Multicenter Uveitis Steroid Treatment (MUST) Trial
7-year follow-up study demonstrates that the usage of
systemic IMT results in improved outcomes compared
to local steroidal therapy [12]. The Fundamentals of Care
for UveitiS (FOCUS) global initiative also recommends a
similar approach to treat noninfectious uveitis [13].
The management of steroid sparing systemic IMT is
complex and frequently beyond the scope of practice
for many ophthalmologists. Furthermore, uveitis is frequently associated with underlying systemic diseases that
require further workup and treatment [13, 14]. Therefore,
many uveitis patients are co-managed with rheumatologists. As a consequence, these patients require frequent
visits to both ophthalmologists and rheumatologists. For
the working-age population, this represents a significant
burden especially if a patient does not have adequate
social support. In our inner-city population in Detroit,
patients are often unable to attend all their appointments,
which can be a barrier to achieving the target dose of
IMT.
In response, we implemented a multidisciplinary model
of non-infectious uveitis management and established a
combined ophthalmology-rheumatology uveitis clinic at
the Kresge Eye Institute where patients were simultaneously managed by a rheumatologist and a uveitis specialist. The goal of this study was to evaluate patient clinical
outcomes of the combined ophthalmology-rheumatology
uveitis clinic and to compare them to those before the
establishment of the clinic. We found the combined clinic
led to more patients at target dose of IMT and a potential
improvement of ocular inflammation and a reduction of
systemic steroid usage.

Materials and methods
Study design

This study was a retrospective analysis of patients comanaged by an ophthalmologist from the Kresge Eye
Institute and a rheumatologist from the Department of
Rheumatology of Wayne State University in the setting of
a combined uveitis clinic. This project was approved by
the Institutional Review Board of Wayne State University
and performed according to the tenets of the Declaration
of Helsinki. Patient written consent was not required.
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Inclusion and exclusion criteria

Patients aged 18 years and older with a minimum
12-month history of chronic uveitis prior to being
referred to the combined uveitis clinic at the Kresge Eye
Institute and who were treated in the combined clinic for
at least 6 months from July 2018 through June 2019 were
included. Patients were excluded if there was no examination data 6 months prior to implementing the combined uveitis clinic or 6 months after their initial visit to
the combined clinic, or if they were not evaluated by the
rheumatologist.
Kresge uveitis clinic logistics

Only patients with immune-mediated uveitis or ocular
inflammatory diseases and on corticosteroid and/or IMT
were referred to the combined uveitis clinic. Prior to the
establishment of the ophthalmology-rheumatology combined uveitis clinic, patients were seen by an ophthalmologist trained in uveitis and rheumatologists separately at
their respective clinics. In the combined clinic, patients
were first seen by the ophthalmologist and then the rheumatologist in a dedicated “uveitis suite” of the Kresge Eye
Institute. When IMT was recommended, the choice and
target dosage of the IMT was determined by the ophthalmologist. The rheumatologist managed the prescription
and side effects of the IMT as well as the systemic rheumatic diseases. In situations in which the rheumatologist
recommended a different treatment plan, the two physicians would consult and come to a consensus.
Data collection

Baseline recorded data included patient demographics
such as age, gender, and race. Biomicroscopic examination of the eyes was carefully performed in each patient
by the ophthalmologist. The following variables were registered in the electronic medical record system: best-corrected visual acuity (BCVA) converted from Snellen to
logMAR scale, location of uveitis (anterior, intermediate,
posterior, panuveitis, or scleritis), and diagnosis (association with systemic autoimmune diseases, or idiopathic).
The diagnoses of systemic diseases were established by
primary care physicians or rheumatologists. Diagnosis of
sarcoidosis required tissue biopsy showing non-caseating granulomatous inflammation. The anterior chamber
(AC) cells and flare were graded according to the Standardization of Uveitis Nomenclature (SUN) Working
Group Grading Scheme for Anterior Chamber Cells and
Flare, respectively [15]. The vitreous haze was graded by
the Nussenblatt Scoring System [16]. Optical coherence
tomography (Cirrus 5000; Carl Zeiss Meditec, Dublin,
CA) was performed to evaluate the thickness of the central retina area. Patients with central retinal thickness
greater than 315 μm with intraretinal and/or subretinal
fluid shown in OCT were considered to have macular
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Table 1 Patient demographics and characteristics
Category
Patients (n)
Females (n, %)
Age (mean±SD)
Race (n, %)
African American
Caucasian
Asian
Middle Eastern
Other/not specified
Uveitis location (n, %)
Anterior
Intermediate
Posterior
Panuveitis
Scleritis
Uveitis association (n, %)
Idiopathic
Sarcoidosis
HLA-B27
Multiple Sclerosis
Vogt-Koyanagi-Harada
Systemic Lupus Erythematosus
Juvenile Idiopathic Arthritis
Behçet’s disease
HLA-A29

Value
74
49 (66.2)
51.5±12.8
63 (85.1)
7 (9.5)
1 (1.4)
1 (1.4)
2 (2.7)
20 (27.0)
3 (4.1)
11 (14.9)
33 (44.6)
7 (9.5)
44 (59.5)
13 (17.6)
5 (6.8)
3 (4.1)
3 (4.1)
2 (2.7)
2 (2.7)
1 (1.4)
1 (1.4)

edema [17]. Treatment plans recorded whether patients
were on corticosteroids and/or IMT, routes of pharmacologic administration, types of pharmacotherapies, and
dosage. Target dose of corticosteroids was defined as
≤ 7.5 mg/day, and target doses of IMT were defined as
> 15 mg/week for oral Methotrexate, > 2 g daily for Mycophenolate mofetil, > 2 mg/kg/day for Azathioprine [18].
Biological agents were considered at target dose based on
clinician assessment.
The primary endpoint was the percentage of patients at
target dose of IMT. Other endpoints included daily oral
steroid dose, BCVA, and objective markers of inflammation, including AC cells and flare, vitreous haze, and central retinal thickness.
Statistical analysis

Samples were described by using mean and standard
error for continuous variables. Continuous data were
analyzed using paired Student’s T test, and categorical data using Fisher’s Exact Test with Prism 9 software
(GraphPad Software, Inc., San Diego, CA). P value < 0.05
was considered statistically significant.

Results
Patient demographics

A total of 135 eyes of 74 patients were included in
this study. The mean age of the patients at the initial
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combined visit was 51.5 ± 12.8 years (range: 20.2–92.4
years) with 66.2% female. The predominant race of
patients was African American (85.1%). Panuveitis was
the most frequent location of uveitis in our study population (33 patients, 44.6%), followed by anterior and posterior uveitis. Idiopathic uveitis accounted for 59.5% of
patients. Uveitis associated with systemic diseases was
diagnosed in 40.5% of patients. The demographic and
uveitis breakdown are summarized in Table 1.
Inflammation status of the eyes

Figure 1 shows the quantifiable objective data from 6
months prior to being referred to the combined clinic,
the first combined clinic visit, and six months after being
treated in the combined clinic. There was a statistically
significant improvement of BCVA from 0.58 logMAR
(Snellen: ~20/74) to 0.50 logMAR (Snellen: ~20/63) after
6 months of the combined clinic (p = 0.0137) (Fig. 1 A).
AC cell grade, which reflects active inflammation in the
eyes, was significantly reduced at the initial combined
visit compared to the 6 months prior visit (SUN scores:
0.50 vs. 0.69, p = 0.0406) (Fig. 1B). Significant improvement of AC flare grade was also observed between the
6 months prior visit and the initial combined visit (0.70
vs. 0.48, p = 0.0272) (Fig. 1 C). No significant difference
was detected in AC cell or flare grade between the initial
combined visit and the 6 months post visit. When evaluating vitreous haze, patients diagnosed with anterior uveitis and scleritis were excluded from the analysis because
their pupils were either not dilated during the visits or
the posterior segments could not be viewed due to pupillary synechiae. A decrease in vitreous haze was detected
between the three visits; however, the decrease was not
statistically significant (Fig. 1D). Macular edema is one of
the structural complications of uveitis and can be evaluated by OCT measuring macular thickness in micrometers [15]. We found the means of macular thickness were
progressively smaller between the three visits (334.8 vs.
309.1 vs. 292.4 μm). However, the changes were not statistically significant (Fig. 1E).
Systemic immunosuppressive therapies

Table 2 shows the types of IMT at these three time
points. The most frequently prescribed immunomodulatory agents in either ophthalmologist only clinic or
the combined clinic were methotrexate, adalimumab,
and mycophenolate mofetil. At the initial combined
visit, more patients were on IMT compared to the 6
months prior visit, 55.4% vs. 31.1%, respectively. In addition, the initial combined visit promoted the usage of
additional immunomodulatory agents: 4 more medications (hydroxychloroquine, dimethyl fumarate, leflunomide, and secukinumab) were introduced in patient
treatment plans. Adjustment of dosages and types of
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Fig. 1 Ophthalmic exam variables evaluated at the initial combined uveitis clinic and 6 months prior to and after the initial combined visits. (A) Best
corrected visual acuity (BCVA) in log MAR scale. (B&C) Anterior chamber (AC) cells and flare graded based on the Standardization of Uveitis Nomenclature (SUN) Working Group Grading Scheme for Anterior Chamber Cells and Flare. (D) Vitreous haze graded by the Nussenblatt Scoring System. When
evaluating vitreous haze, patients with anterior uveitis and scleritis were excluded from the analysis (see Results for more detail). (E) Optical coherence
tomography (OCT) was performed to evaluate the thickness of the central macula. Paired Student’s T test. * p <0.05, ns: not significant

immunomodulatory agents was observed at the 6 months
post visit. These data demonstrate that the combined
effort led to increased utilization and variety of IMT.
The percentage of patients at target dose of IMT and
the average daily oral steroid dosages are shown in Fig. 2.
Compared to 6 months prior to being treated in the
combined clinic, the percentage of patients reaching target dose of the IMT increased from 49.0 to 70.1.4% and
79.8% at the initial combined visit and 6 months after the
combined visit, respectively. The average systemic prednisone dose also decreased from 15.1 mg to 10 mg from 6
months prior to 6 months after the combined visit.

Discussion
Uveitis is commonly associated with systemic rheumatologic conditions which require assessment and management by rheumatologists [13, 14]. In addition, the use of
IMT to manage uveitis and/or the associated systemic
diseases requires the expertise of rheumatologists. This
often necessitates multiple separate office visits with
the potential of lost communication and poor patient
follow-up. A combined uveitis clinic potentially lessens
the patient burden of visits to multiple providers, minimizes potential delays in therapy, and reduces poor clinical outcomes. In this study, we evaluated patient clinical
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Fig. 2 Comparison of the frequency and dosage of systemic immunosuppressive therapies used in patients between the initial combined visit and 6
months prior to and after the initial combined visits. (A) The frequency of patients at target dosage of systemic immunomodulatory therapy (IMT). Fisher’s
exact test. * p <0.05. ** p <0.01. (B) The average of daily systemic corticosteroid dosage at the three visits. Paired Student’s T test. ns: not significant

outcomes of a combined uveitis clinic in which an ophthalmologist and a rheumatologists managed patients
simultaneously, and to compare them to those before the
establishment of the clinic. We found the combined effort
led to increased utilization of IMT and more patients at
target dose of IMT, with a potential improvement of ocular inflammation and reduction of systemic steroid usage.
Logistically, it is difficult to establish a combined ophthalmology-rheumatology clinic, but when established,
the treatment outcomes seem favorable. The HorstBruinsma group in the Netherlands utilized a similar
approach with multidisciplinary team meetings and a
specialized ocular rheumatology outpatient clinic, to
which ophthalmologists could refer patients [19]. They
reported that these forms of multidisciplinary team collaboration generates favorable clinical outcomes: supporting the usage of IMT, tapering corticosteroid dosage,
and leading to new diagnoses of underlying systemic diseases [19]. The clinical approach described is different
from our combined clinic. Practically, it may be difficult
to have frequent multidisciplinary meetings for uveitis,
but a combined clinic may be more feasible. To the best
of our knowledge, this is the first analysis of clinical outcome data from a combined ophthalmology-rheumatology clinic in North America.
While corticosteroids remain the mainstay of treatment
to control active uveitis, serious systemic and ocular side
effects, such as hyperglycemia and glaucoma, respectively, render this treatment option practical for only
a short period of time [20–22]. The need for long-term

therapy for chronic uveitis and possible associated systemic autoimmune diseases, therefore, necessitates
the prescription of immunomodulatory agents which
requires co-management with rheumatologists for careful monitoring of disease activities and medication side
effects [18, 19, 23]. Previous studies have demonstrated
that one of the most important reasons for ophthalmologists to consult rheumatology is the need for therapeutic
advice regarding systemic IMT [19]. A recent report concerns that the majority of ophthalmologists are not familiar with the usage of IMT in managing uveitis, leading to
delays in corticosteroid tapering [24]. Our study showed
that the combined uveitis clinic resulted in more frequent
prescriptions of IMT and also a greater variety of immunomodulatory agents used to control uveitis and/or associated systemic autoimmune diseases. These joint efforts
increased the number of patients at target dosage of IMT,
demonstrating the effectiveness of the collaboration.
Although the change in visual acuity after the initial
combined uveitis clinic was statistically significant, the
improvement may not be clinically significant. Visual
acuity may not be a meaningful marker for the benefits
of the combined clinic as they can be affected by other
ocular comorbidities. Interestingly, our data shows that
the improvement in most of the other quantifiable markers of inflammation did not reach statistical significance.
This is contrary to the expectation that offering a combined clinic would decrease the appointment burden and
improve patient attendance, consequently allowing better inflammation control. However, from our experience,
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Table 2 The number and frequency of patients on individual
immunomodulatory agent
Immunomodulatory therapy (IMT)
6 months prior
Not on IMT
Methotrexate
Adalimumab
Mycophenolate mofetil
Azathioprine
Infliximab
Tacrolimus
Cyclosporine
Sulfasalazine
Ocrelizumab
Etanercept
Initial combined visit
Not on IMT
Methotrexate
Adalimumab
Mycophenolate mofetil
Infliximab
Azathioprine
Tacrolimus
Cyclosporine
Sulfasalazine
Hydroxychloroquine
Dimethyl fumarate
Leflunomide
Secukinumab
Ocrelizumab
Etanercept
6 months after
Not on IMT
Methotrexate
Adalimumab
Mycophenolate mofetil
Azathioprine
Infliximab
Leflunomide
Sulfasalazine
Dimethyl fumarate
Tocilizumab
Golimumab

N (%)
51 (68.9)
17 (23.0)
6 (8.1)
5 (6.8)
3 (4.1)
3 (4.1)
2 (2.7)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
33 (44.6)
26 (35.1)
11 (14.9)
10 (13.5)
5 (6.8)
4 (5.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
34 (45.9)
23 (31.1)
11 (14.9)
9 (12.2)
6 (8.1)
4 (5.4)
2 (2.7)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)

patients with uveitis tend to seek ophthalmological
evaluation during an acute uveitis flare, i.e. when inflammation worsens, which can be controlled with local and
systemic steroids. Therefore, inflammation control at
predefined time points, as in our study (e.g. prior to and
after the combined clinic) may not differ significantly.
In our population, rheumatology appointments were
more commonly missed, especially when the eye was
asymptomatic, and the suboptimal dose of IMT in these
patients would be a barrier to achieving long-term control. It is possible that there were more uveitis flares prior
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to implementing the combined clinic, but this was not
easily quantifiable for our study duration.
There are several limitations in this study. Firstly, our
sample size is relatively small. The small sample size, in
combination with the large variation of patients who had
uveitis, increases the chance of type 2 error in our study.
This may partially account for the lack of significant differences in ocular inflammatory variables after the initial combined clinic visit. Secondly, the short duration
of follow-up time in our study limits the potential for
revealing the benefits of the combined clinic. It is possible that as follow-up duration increases, a greater proportion of patients will achieve the target dose of IMT,
and the reduction of average systemic corticosteroid dose
will reach statistically and clinically significance. Thirdly,
the retrospective nature of the study was not able to control confounders and limits the definiteness of the conclusion. However, given the likelihood of improved IMT
management found in this study, it may not be appropriate to randomize patients to combined versus separate
ophthalmology and rheumatology clinics. Rather, it may
be preferable to compare outcomes in institutions where
both combined and separate uveitis-rheumatology clinics
exist. Finally, 85.1% of our patients are African American.
Although the exact demographic and distribution of systemic associations may not be the same in other cohorts,
we believe the findings of improved IMT management in
a combined clinic is likely generalizable.

Conclusion
The primary goals of uveitis management are to better
control disease activity and prevent vision deterioration
while frequently transitioning patients from corticosteroid therapy to IMT. This study is the first to show benefits in improvement in IMT management in a combined
ophthalmology-rheumatology clinic compared to when
patients were separately managed. If feasible, this would
be the preferred approach to manage uveitis in practices
with high volume of uveitis patients.
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